Lilly and Foghorn enter partnership to develop new cancer medicines
Eli Lilly and Company’s research and development group Loxo Oncology at Lilly and Foghorn Therapeutics have entered a strategic partnership to develop new cancer therapies.
December 15, 2021
by Pharmaceutical-Technology
Lilly and Merus partner to develop T-Cell re-directing antibody therapies
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
January 21, 2021
by pharmaceutical-technology
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology...
February 18, 2019
by worldpharmanews
Lilly Announces Agreement to Acquire Loxo Oncology
Eli Lilly and Company and Loxo Oncology announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion ......
January 8, 2019
by americanpharmaceuticalreview
Blueprint’s Tagrisso combination shows early promise in NSCLC
Based on these data, Blueprint is looking into testing the combination in more patients with the same treatment-resistant EGFR-mutant cancer.
September 28, 2018
by fiercebiotech
Deals this week: Carma Therapeutics, Vectorite Biomedica, Loxo Oncology
Cellular immunotherapies developer Carma Therapeutics has completed a venture financing round co-led by AbbVie Biotech Ventures and HealthCap in order to raise funds required to advance the development of its adoptive cellular immunotherapy named CARMA-05
June 19, 2017
by pharmaceutical-technology